Clinical Drug Trial #1

Type of Project: Multi-center Clinical Drug Trial
Methods: Neurological and Neuropsychological Testing
Status: Funding secured from Myriad Pharmaceuticals
Study Period: November 1, 2006 – June 1, 2008
In Collaboration With: Myriad Pharmaceuticals
University of Utah Collaborative Units: Department of Neurology
Investigators: Edward Zamrini, M.D. (Site Principal Investigator), James A. Levy, Ph.D., Rebecca Mesley, B.S.

Project Summary:

This is a phase III, multinational, randomized, double-blind, placebo-controlled clinical trial to determine the efficacy of a new drug for treating Alzheimer’s disease. Drug or placebo will be given to patients with mild dementia due to probable Alzheimer’s disease. This drug is a member of a new class of drugs that may alter a basic mechanism of Alzheimer’s disease.

Some early research studies have shown that people who take anti-inflammatory drugs (such as aspirin or ibuprofen) may have a lower chance of developing Alzheimer’s disease. One of these anti-inflammatory drugs is called flurbiprofen. This drug is approved for use by the FDA. An ingredient of flurbiprofen, called MPC-7869, has been chosen to be studied as a possible treatment for Alzheimer’s disease. This ingredient (MPC-7869) is the investigational drug that will be studied in this trial. ClinicalTrials.gov identifier: NCT00322036.

Potential Benefits:

This study could identify a new treatment for Alzheimer’s disease. It would have the advantage over current treatments of altering the course of disease and slowing the progression of memory loss and other symptoms.